Pulmonary hypertension owing to lung disease and/or hypoxia

This study looked at the long-term safety of an inhaled medication called treprostinil palmitil (TPIP) for people with pulmonary hypertension caused by interstitial lung disease. Thirty-one adults who completed a previous study took part. The main goal was to check for side effec…

This study looked at how an inhaled drug called treprostinil helps patients with pulmonary hypertension caused by interstitial lung disease. Researchers measured heart function and breathing efficiency during exercise after 3 months of treatment. The goal was to understand how th…

This completed Phase 1 study looked at 27 people with and without pulmonary hypertension to learn more about how blood vessel problems contribute to the disease. Researchers used heart catheterization, imaging, and blood tests to find biomarkers and understand disease mechanisms.…

This study followed 72 adults with pulmonary hypertension caused by chronic lung diseases, like interstitial lung disease, who were treated with inhaled iloprost in routine care. Researchers tracked changes in their risk levels over time using a standard scoring model. The goal w…